Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:11 AM
Ignite Modification Date:
2025-12-25 @ 5:11 AM
NCT ID:
NCT00292227
Eligibility Criteria:
Inclusion Criteria:
* Male or female at least 18 years of age
* Advanced-stage idiopathic Parkinson's disease requiring treatment with levodopa.
* Nonchildbearing potential
Exclusion Criteria:
* Atypical Parkinson's syndrome(s).
* History of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant.
* Significant tremor or dyskinesias.
* Severe dysfunction of the autonomic nervous system.
* History of transient ischemic attack or stroke within the last 12 months.
* Conduction abnormality or relevant cardiac dysfunction and/or myocardial infarction within last 12 months.
* History or current condition of additional risk factors for Torsade de Pointes (eg, heart failure, hypokalemia), or a family history of long QT syndrome and/or of Torsade de Pointes.
* No stable sinus rhythm: more than 20 ectopics/h.
* Any other clinically relevant ECG abnormality.
* History or current condition of epilepsy and/or seizures.
* History or current condition of atopic or eczematous dermatitis, psoriasis, or another active skin disease.
* History or current condition of symptomatic orthostatic hypotension.
* History or current condition of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis.
* History of glucose 6-phosphate dehydrogenase deficiency.
* History of tendonitis or tendon rupture with quinolone antibiotics.
* Renal or hepatic dysfunction.
* Treatment with dopamine agonists, MAO A inhibitors, reserpine, or alpha-methyldopa
* Therapy known to produce a nontrivial prolongation of the QT interval.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00292227
Study Brief:
Protocol Section:
NCT00292227